Top

Clinical Oral Investigations

Published in:

Open Access 01-05-2016 | Original Article

Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow

Authors: Shinichiro Kuroshima, Zeina Al-Salihi, Junro Yamashita

Published in: Clinical Oral Investigations | Issue 4/2016

Abstract

Objectives

Denosumab, a human monoclonal antibody (mAb) that neutralizes receptor activator for nuclear factor κB ligand (RANKL), is associated with osteonecrosis of the jaw. However, the effect of denosumab on oral wounds is unclear. The aim was to determine the effect of anti-RANKL mAb on oral wounds and bone marrow.

Materials and methods

The direct effect of the mAb on fibroblasts, macrophages, and osteoclasts were assessed in vitro. In vivo, mouse anti-RANKL mAb was administered to mice for 9 weeks prior to palatal bone denudation surgery. Mice were euthanized 3 weeks post-surgery, and wound healing was histomorphometrically analyzed. Long bones were assessed using micro-computed tomography, quantitative real-time polymerase chain reaction, and flow cytometry.

Results

The mAb had no effect on macrophages and fibroblasts but significantly suppressed osteoclast proliferation in vitro. The mAb treatment significantly increased bone mass by suppressing osteoclasts in vivo. The expression of pro-osteoclastic genes was promoted in the bone marrow of the mAb-administered animals. Consistently, the mAb significantly induced the development of tartrate-resistant acid phosphatase (TRAP)-positive mononuclear cells (MNCs) but not osteoclasts in bone marrow. The mAb treatment had no effect on gross healing of the palatal wounds. However, significant inflammation was retained in the connective tissue facing the once denuded bone surface.

Conclusions

Repair of the damaged palate was delayed, and significant inflammation was sustained in the connective tissue by anti-RANKL mAb treatment.

Clinical relevance

Denosumab impairs osteoclastic bone repair. Care should be exercised to minimize osseous trauma when invasive procedures are performed on patients taking denosumab.

Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53–62CrossRefPubMedPubMedCentral

Jain N, Weinstein RS (2009) Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nat Rev Rheumatol 5:341–346CrossRefPubMedPubMedCentral

Jobke B, Milovanovic P, Amling M, Busse B (2014) Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients. Bone 59:37–43CrossRefPubMed

Kuroshima S, Go VA, Yamashita J (2012) Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice. Endocrinology 153:17–28CrossRefPubMedPubMedCentral

Kuroshima S, Yamashita J (2013) Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice. Bone 56:101–109CrossRefPubMed

Kuroshima S, Entezami P, McCauley LK, Yamashita J (2014) Early effects of parathyroid hormone on bisphosphonate/steroid-associated compromised osseous wound healing. Osteoporos Int 25:1141–1150CrossRefPubMedPubMedCentral

Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767–774CrossRefPubMed

Lewiecki EM, Bilezikian JP (2012) Denosumab for the treatment of osteoporosis and cancer-related conditions. Clin Pharmacol Ther 91:123–133CrossRefPubMed

Kimmel DB (2007) Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86:1022–1033

10.

Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–1066CrossRefPubMed

11.

Malan J, Ettinger K, Naumann E, Beirne OR (2012) The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 114:671–676CrossRef

12.

Neuprez A, Coste S, Rompen E, Crielaard JM, Reginster JY (2014) Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporos Int 25:393–395CrossRefPubMedPubMedCentral

13.

Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 24:182–195CrossRefPubMed

14.

Furuya Y, Mori K, Ninomiya T, Tomimori Y, Tanaka S, Takahashi N, Udagawa N, Uchida K, Yasuda H (2011) Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts. J Biol Chem 286:37023–37031CrossRefPubMedPubMedCentral

15.

Matsubara R, Kukita T, Ichigi Y, Takigawa I, Qu PF, Funakubo N, Miyamoto H, Nonaka K, Kukita A (2012) Characterization and identification of subpopulations of mononuclear preosteoclasts induced by TNF-α in combination with TGF-β in rats. PLoS One 7, e47930CrossRefPubMedPubMedCentral

16.

Kukita T, Wada N, Kukita A, Kakimoto T, Sandra F, Toh K, Nagata K, Iijima T, Horiuchi M, Matsusaki H, Hieshima K, Yoshie O, Nomiyama H (2004) RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med 200:941–946CrossRefPubMedPubMedCentral

17.

Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Hanning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, Levy MA (1996) Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 271:12517–12524

18.

Thompson ER, Baylink DJ, Wergedal JE (1975) Increases in number and size of osteoclasts in response to calcium or phosphorus deficiency in the rat. Endocrinology 97:283–289CrossRefPubMed

19.

Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM (2002) In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 17:192–199CrossRefPubMed

20.

Schwarz EM, Ritchlin CT (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther 9(Suppl 1):S7CrossRefPubMedPubMedCentral

21.

Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408:600–605

22.

Beetz S, Wesch D, Marischen L, Welte S, Oberg HH, Kabelitz D (2008) Innate immune functions of human gammadelta T cells. Immunobiology 213:173–182CrossRefPubMed

23.

Nanno M, Shiohara T, Yamamoto H, Kawakami K, Ishikawa H (2007) Gammadelta T cells: firefighters or fire boosters in the front lines of inflammatory responses. Immunol Rev 215:103–113CrossRefPubMed

24.

Yamashita J, Koi K, Yang DY, McCauley LK (2011) Effect of zoledronate on oral wound healing in rats. Clin Cancer Res 17:1405–1414CrossRefPubMedPubMedCentral

25.

Gan X, Huang S, Liu Y, Yan SS, Yu H (2014) The potential role of damage-associated molecular patterns derived from mitochondria in osteocyte apoptosis and bone remodeling. Bone 62:67–68CrossRefPubMed

Title: Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow
Authors: Shinichiro Kuroshima
Zeina Al-Salihi
Junro Yamashita
Publication date: 01-05-2016
Publisher: Springer Berlin Heidelberg
Published in: Clinical Oral Investigations / Issue 4/2016
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI: https://doi.org/10.1007/s00784-015-1550-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Mouse anti-RANKL antibody delays oral wound healing and increases TRAP-positive mononuclear cells in bone marrow

Abstract

Objectives

Materials and methods

Results

Conclusions

Clinical relevance

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Materials and methods

Results

Conclusions

Clinical relevance

Please log in to get access to this content

Other articles of this Issue 4/2016

Is there an association between obstructive sleep apnea syndrome and periodontal inflammation?

Clinical evaluation comparing the fit of all-ceramic crowns obtained from silicone and digital intraoral impressions

Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Erlotinib and gefitinib responsiveness in head and neck cancer cell lines—a comparing analysis with cetuximab

Salivary and serum interleukin-6 levels in proliferative verrucous leukoplakia

Regenerative endodontic procedure of an infected immature permanent human tooth: an immunohistological study